Original Research J Clin Psychiatry April 2026

A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Article Summary Cognitive impairment associated with schizophrenia is a major driver of poor long-term functional outcomes, yet no approved treatment is available. This trial tested whether adjunctive basmisanil could improve cognition in clinically stable patients and whether age or cognitive subtype could help identify a responder group. FAQ Did basmisanil improve cognition in schizophrenia in this phase 2b trial? 11 questions
Key Takeaways The 80 mg arm was stopped after interim futility analysis because it had a less than 20% probability of reaching an effect size of at least 0.35, supporting early discontinuation of underperforming CIAS doses in adaptive trial designs. 6 takeaways · 5 clinical pearls Clinical Guide How can clinicians and trialists structure cognitive assessment in schizophrenia studies to reduce practice and placebo effects? 6 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen to the JCP Podcast Now
Figure: Digital illustration shows a human head with neural connections and podcast title over a dark blue patterned background.

Subscribe to read
more articles

Subscribe